Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

NCT07109765 | Recruiting

• 1 other identifier: No. I-24PJ1844
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Conditions

Hidradenitis Suppurativa (HS)

Keywords

Hidradenitis Suppurativa; Secukinumab; ultrasound

Outcome Measures

Primary Outcomes (1)

• Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

  a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels

  From enrollment to the end of treatment at Week 12

Secondary Outcomes (1)

• Dermatology Life Quality Index

  From enrollment to the end of treatment at week 12

Interventions

Secukinumab DRUG

secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All participants were treated at the Department of Dermatology, Peking Union Medical College Hospital

You may qualify if:

• age ≥18 years
• diagnosis of moderate-to-severe HS with Hurley stage II or III
• Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
• inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors

You may not qualify if:

• active infections (e.g., viral hepatitis, active tuberculosis)
• use of other biologics or systemic immunosuppressants within the past three months
• severe organ dysfunction (e.g., hepatic or renal failure)
• any other conditions that might affect study results

Sponsors & Collaborators

• Peking Union Medical College: lead

Study Sites (1)

No. 1 Shuai Fu Yuan, Dongcheng District, Beijing

Beijing, Beijing Municipality, 100730, China

RECRUITING

MeSH Terms

Conditions

Hidradenitis Suppurativa

Interventions

secukinumab

Condition Hierarchy (Ancestors)

Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration; Skin Diseases; Skin and Connective Tissue Diseases; Hidradenitis; Sweat Gland Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident physician of dermatology

Study Record Dates

• First Submitted: July 31, 2025
• First Posted: August 7, 2025
• Study Start: June 1, 2025
• Primary Completion: June 1, 2026
• Study Completion: June 1, 2026
• Last Updated: August 7, 2025

Record last verified: 2025-07

Locations

CN (1)